Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, at 40 Guest Street. The company's core business revolves around developing a novel class of therapeutic biologics designed to selectively engage and modulate disease-relevant T cells. Its mission is to revolutionize immunotherapy, creating more effective treatments for challenging diseases and transforming patient care in oncology and autoimmune disorders by harnessing the power of the immune system to establish a new standard of care.

At the heart of Cue Biopharma's approach is its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T Cells) platform, which engineers biologics to mimic natural immune signals to selectively expand and activate specific immune cells, aiming to restore immune function and balance. The company's pipeline includes the CUE-100 series for oncology, the CUE-400 series for autoimmune diseases, and the CUE-500 series for targeted cell depletion, also addressing autoimmune and inflammatory conditions. Key product candidates include CUE-101 in oncology, CUE-401 for autoimmune diseases advancing towards Phase 1, and CUE-501. Additionally, Cue Biopharma recently expanded its pipeline by licensing Ascendant-221, a Phase 2 clinical-stage anti-IgE antibody for allergic diseases.

In recent notable developments, Cue Biopharma announced the appointment of Shao-Lee Lin, M.D., Ph.D., as its new Chief Executive Officer, President, and Director on April 30, 2026. This leadership change coincided with a significant expansion of its pipeline through an exclusive license agreement with Ascendant Health Sciences Ltd. for Ascendant-221, involving a $15 million upfront payment and potential milestones up to $676.5 million. The company also secured a $30 million private placement financing to advance its clinical pipeline and for general corporate purposes. Cue Biopharma is currently implementing a 1-for-30 reverse stock split. The company is positioned as a clinical-stage biopharmaceutical firm focused on delivering targeted immunotherapies across high-growth sectors of oncology and autoimmune/inflammatory diseases, aiming to avoid the adverse effects associated with broad systemic immune modulation.